World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

A REVIEW ON PREVENTION AND MANAGEMENT OF CONGESTIVE HEART FAILURE

Ankit Sharma, Toshar Thakur Sanjeev Kumar, Shivani Thakur, Priti Pathania, Tanish and Sahil Kumar

ABSTRACT

Congestive heart failure (CHF) is a prevalent and serious condition that affects millions globally, characterized by the heart’s inability to pump blood effectively, leading to a buildup of fluid in the lungs and other parts of the body. This report provides a comprehensive overview of the management and treatment strategies for CHF, with an emphasis on both pharmaco logical and non pharmacological approaches. Key pharmacologic intervent ions, including angiotensin converting enzyme inhibitors (ACE inhibitors), beta blockers, and diuretics, are discussed in relation to their mechanisms of action and clinical effectiveness in symptom management and survival improvement. Additionally, device based therapies such as implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are reviewed for their role in advanced stages of the disease. Non pharmacological treatments, including lifestyle modifications, dietary re commendations, and patient education, are also highlighted as essential components in improving quality of life and preventing disease progression. The report concludes with an emphasis on a multidisciplinary approach to CHF management, stressing the impor tance of personalized treatment plans and ongoing patient monitoring to achieve optimal outcomes.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR